My perspective is that sales of Novosorb are growing strongly enough that they feel they can afford to take their time over the DFU trial revamp and concentrate on the BARDA burns trial which will provide a pathway to greater reimbursement and drive market share.
In the future a good DFU trial result might result might open the way to further IP enhancements, business acquistion and drive growth into 2026/2027?
My perspective is that sales of Novosorb are growing strongly...
-
- There are more pages in this discussion • 232 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.43 |
Change
-0.090(3.57%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $2.49 | $2.50 | $2.43 | $2.311M | 940.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17100 | $2.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.45 | 5973 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |